Effectiveness of Chlorhexidine Wipe for Prevention of Multidrug-resistant Organisms in Intensive Care Unit Patients
Overview
The purpose of this study is to determine 2% chlorhexidine wipes are effective in preventing of colonization of multi-drug resistant bacteria in intensive care unit patients.
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Prevention
- Masking: None (Open Label)
- Study Primary Completion Date: January 2015
Detailed Description
The purpose of this study is to evaluate the usefulness of bathing with chlorhexidine wipe to reduce the risks of multidrug resistant bacteria acquisition and hospital-acquired bloodstream infection among ICU patients
Interventions
- Drug: 2% chlorhexidine wipe
- The ICU patients will be bathing with 2% chlorhexidine wipe
- Drug: Soap
- The ICU patients will be bathing with Soap
Arms, Groups and Cohorts
- Placebo Comparator: Soap bathing
- ICU patients will be bathing with soap at least once daily
- Experimental: 2% chlorhexidine wipes
- Use 2% chlorhexidine wipes to clean the patient at least once daily
Clinical Trial Outcome Measures
Primary Measures
- The overall rate of Multidrug resistant bacteria acquisition at 7 days after received 2% chlorhexidine wipe bathing versus with soap bathing
- Time Frame: 7 days after recieved 2% chlorhexidine wipes
- 7 days after received 2% chlorhexidine wipes,the microbiology laboratory will process surveillance specimens using either standard culture-based at both nostrils, axillar, groins, rectum
Secondary Measures
- The overall rate of hospital-acquired bloodstream infections per 1000 patient-days with chlorhexidine wipe bathing versus with soap bathing
- Time Frame: 48 hours after recieved 2% chlorhexidine wipes
Participating in This Clinical Trial
Inclusion Criteria
- Age > 18 years – Admission in critical care unit eg. ICU, respiratory care unit, Cardiac care unit with in 24 hours – Expected duration of critical care unit admission > 48 hours Exclusion Criteria:
- History of chlorhexidine allergy
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 95 Years
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- Mahidol University
- Provider of Information About this Clinical Study
- Principal Investigator: Adhiratha Boonyasiri, Doctor – Mahidol University
- Overall Official(s)
- Adhiratha Boonyasiri, MD, Principal Investigator, Mahidol University
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.